International Journal of Industrial Entomology and Biomaterials

Korean Society of Sericultural Science (한국잠사학회)
권호 표지

Antiviral Potential of the Silkworm Deoxynojirimycin against Hepatitis B Virus

  • You, Jung-Eun (Department of Life Science, College of Natural Sciences, The University of Suwon) ;
  • Seong, Su-Il (Department of Life Science, College of Natural Sciences, The University of Suwon) ;
  • Kim, Young-Ho (Department of Life Science, College of Natural Sciences, The University of Suwon)
  • Published : 2003.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Over 350 million people worldwide are chronic carriers of hepatitis B virus (HBV). Chronic viral infections of the liver can progress to cirrhosis, which may ultimately lead to hepatic failure or the development of hepatocellular carcinoma. There are two antiviral drugs on the market approved for clinical management of chronic HBV infections; interferon-alpha and the nucleoside analog lamivudine. However, they showed adverse side-effects. In the rational drug design for such therapies we would like to utilize antiviral drugs that inhibit the HBV replication in the liver. Investigation of natural extracts of silkworm exhibiting antiviral potential was held in the functional HBV polymerase activity and the release of virion particle in the HepG2.2.15 cell lines. HBV-producing transgenic mouse fed with silkworm DNJ molecule was shown as an inhibitor of serum HBV particles. We could represent this DNJ molecule as an antiviral potential complementing conventional therapies after preclinical tests against WHBV-infected animal model, woodchuck.

Keywords

References

  1. Blumberg, B. S. (1998) Hepatitis B virus: search for plant-derived antiviral; in Medical plants-their role in healh and biodiversity. Tomlinson T. R. and D. Akerele (eds.), PP. 7, University of Pennsylvania Press, Philadelphia
  2. Chen, R. W., H. Piparinen, M. Seppanen, P. Koskela, S. Sama and M. Lappalainen ( 2001) Real-time PCR for detection andquantitation of hepatitis B virus DNA. J. Med. Virol. 65, 250-256 https://doi.org/10.1002/jmv.2027
  3. Fischer, P. B., G. B. Karlsson, R. A. Dwek and F. M. Platt (1996) N-butyldeoxynojirimycin-mediated inhibition ofHIV virus entry correlates with impaired gp120 shedding and gp41 exposure. J. Virol. 70, 7] 53-7160
  4. Hu, J. and C. Seeger (1996) Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 93, 1060-1064 https://doi.org/10.1073/pnas.93.3.1060
  5. Korba, B. E. and J. L. Gerin (1992) Use of a standadized cell culture assay to assess activities of nucleoside analogs against HBV replication. Antiviral Res. 19, 55-70 https://doi.org/10.1016/0166-3542(92)90056-B
  6. Korba, B. E. and G. Milman (1991) A cell culture assay for compounds which inhibit HBV replication. Antiviral Res. 15, 217-228 https://doi.org/10.1016/0166-3542(91)90068-3
  7. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacte.nophage $7_4$. Nature 227, 680-685 https://doi.org/10.1038/227680a0
  8. Lanford, R. E., L. Notvall and B. Beames (1995) Nucleotide phming and reverse transcnptase activity of Hepatitis B Virus polymerase expressed in insect cells. J. Virol. 69, 4431-4439
  9. Lanford, R. E., Y. H. Kim, H. Lee, L. Notvall and B. Beames (1999) Mapping ofthe HBV reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and protein-protein interaction. J. Virol. 73, 1885-1893
  10. Liaw, Y. F. (1997) Current trends in therapy for chronic viral hepatitis. J. Gastromterol. Hepatol. 12, S346-S353 https://doi.org/10.1111/j.1440-1746.1997.tb00520.x
  11. Liu, J. M., H. Lin and H. Mclntosh (2001) Genus Phyllanthus for chronic hepatitis B Virus infection: a systematic review. J. Viral Hepatitis 8, 358-366 https://doi.org/10.1046/j.1365-2893.2001.00307.x
  12. Lu, X., A. Mehta, M. Dadmarz, R. Dwek, B. Blumberg and T. Block (1997) Aberrant trafficking of hepatitis B virus glyco-proteins in cells in which N-glycan processing is inhibited. Proc. Natl. Acad. Sci. USA 94, 2380-2385 https://doi.org/10.1073/pnas.94.6.2380
  13. Mehta, A., S. Carrouee, B. Conyers, R. Jordan, T. Butters, R.Dwek and T. M. Block (2001) Inhibition of HBV DNA repli-cation by imino sugars without the inhibition of the DNA polymerase- therapeutic implications. Hepatology 33, 1488-1495 https://doi.org/10.1053/jhep.2001.25103
  14. Mehta, A., X. Lu, T. M. Block, B. S. Blumberg and R. A. Dwek (1997) HBV envelop glycoproteins vary drastically in their sensitivity to glycan processing: Evidence that alter-ation of a single N-linked glycosylation site can regulate HBV secretion. Proc. Natl. Acad. Sci. USA 94, 1822-1827 https://doi.org/10.1073/pnas.94.5.1822
  15. Mehta, A., N. Zitzmann, P. Rudd, T. Block and R. Dwek (1998) Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Letter 430, 17-22 https://doi.org/10.1016/S0014-5793(98)00525-0
  16. Park, S. G. and G. Jung (2001) Human Hepatitis B Vims polymerase interacts with the molecular chaperonin Hsp60. J. Virol. 75, 6962-6968 https://doi.org/10.1128/JVI.75.15.6962-6968.2001
  17. Purcell, R. H. (1990) The discovery ofthe hepatitis virus. Gas-troenteroloey 104, 955-963
  18. Saunier, B., R. D. Kilker, J. S. Tkacz, A. Quaroni and A. Hers-covics (1982) Inhibition of N-linked complex oligosaccha-ride formation by l-DNJ, an inhibitor of processing glucosidases. J. Biol. Chem. 257, 14155-14161
  19. Seeff, L. B., K. L. Lindsay, B. R. Bacon, T. F. Kresina and J. H. Hoofnagle (2001) Complementary and altemative medicine in chronic liver disease. Hepatology 34, 595-603 https://doi.org/10.1053/jhep.2001.27445
  20. Sells, M. A., M. L. Chen and G. Acs (1987) Production of HBV virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84,1005-1009 https://doi.org/10.1073/pnas.84.4.1005
  21. Wang, G. H. and C. Seeger (1992) the reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA syn-thesis. Cell 71, 663-670 https://doi.org/10.1016/0092-8674(92)90599-8
  22. Werr, M. and R. Prange (1998) Role for calnexin and N-linked glycosylation in the assembly and secretion of HBV virus middle envelope protein particles. J. Vtrol. 72, 778-782
  23. WHO. Hepatitis B. Fact Sheet WH0/204, November 1998
  24. Zitzmann, N., A. S. Mehta, S. Carrouee, T. D. Butters, F. M. Platt, J. McCauley, B. S. Blumberg, R. A. Dwek and T. M Block (1999) Imino sugars inhibit the formation and secre-tion of BVDV vims, a pestivims model of HCv: Implications for the development of broad spectrum anti-hepatitis vims agents. Proc. Natl. Acad. Sci. USA 96, 11878-11882 https://doi.org/10.1073/pnas.96.21.11878
  25. Zoulim, F. and C. Seeger (1994) Reverse transchption in hepa titis B virus is primed by a tyrosine residue of the poly-merase. J. Virol. 68, 6-13
  26. Zoulim, F, J. Saputelli and C. Seeger (1994) Woodchuck HBV virus X protein is required for viral infection in vivo. J. Virol.68, 2026-2030